Ambrx Lands New Merck Serono Deal, This Time In Multiple Sclerosis

After boosting staff by 50 percent, Ambrx has cash runway through late 2011 or 2012, CEO says.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet